At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
Most Recent Events
- 13 Jul 1998 Profile reviewed
- 13 Jul 1998 No-Development-Reported for Cancer in USA (Unknown route)
- 25 Nov 1994 ADIS 3510 is now called AHMA